Loading...
| A03334 | Pages: NA | Feb 2022 | 4839 Views | | |
| Author(s) : NA | Tables: NA | Charts: NA |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Naftifine Hydrochloride Ointment Market
Request Now !Naftifine hydrochloride (naftifine), chemically known as (E)-N-Cinnamyl-N-methyl-1-napthalenemethylamine hydrochloride is an antifungal drug used to topically treat fungal infections such as tinea pedis (athletes foot), tinea cruris (jock itch), tinea corporis (ringworm), and others. It is a synthetic allylamine antifungal compound. Naftifine is only prescribed for topical application. This ointment has a complete anti-microbial mechanism of action comprising anti-fungal, anti-bacterial, and anti-inflammatory activity.
Rise in awareness boosts the growth of the market. Furthermore, increase in prevalence rate of fungal infections and rise in disposable income of population are key factors that propel the naftifine hydrochloride ointment market. However, minor side effects associated with this drug and stringent government regulations toward naftifine hydrochloride impede the growth of this market to a certain extent.
The global methadone market is segmented on the basis of patient group, distribution channel and geography. Based on patient group, the market is bifurcated into adults and children. On the distribution channel, this market is segmented into hospital pharmacy, retail pharmacy, and ecommerce. By geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Merz Dermatology, Parchem Fine & Specialty Chemicals, LGM Pharma, Sebela Pharmaceuticals, Inc., Erregierre S.P.A., Simagchem Corporation, Taro Pharmaceutical Industrues, Ltd., Renaissance Pharma, Inc., Shanghai Yisa Biotechnology Co., Ltd. and Shaanxi TOP Pharm Chemical Co., Ltd. provided in this report.
Key Benefits:
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 NAFTIFINE HYDROCHLORIDE OINTMENT MARKET, BY PATIENT GROUP
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. ADULTS
4.2.1. Market size and forecast
4.3. CHILDREN
4.3.1. Market size and forecast
CHAPTER 5 NAFTIFINE HYDROCHLORIDE OINTMENT MARKET, BY DISTRIBUTION CHANNEL
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. HOSPITAL PHARMACY
5.2.1. Market size and forecast
5.3. RETAIL PHARMACY
5.3.1. Market size and forecast
5.4. E-COMMERCE
5.4.1. Market size and forecast
CHAPTER 6 NAFTIFINE HYDROCHLORIDE OINTMENT MARKET, BY GEOGRAPHY
6.1. OVERVIEW
6.2. NORTH AMERICA
6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast
6.2.3.1. U.S. market size and forecast
6.2.3.2. Canada market size and forecast
6.2.3.3. Mexico market size and forecast
6.2.4. North America Naftifine Hydrochloride Ointment Market by Patient Group
6.2.5. North America Naftifine Hydrochloride Ointment Market by Distribution Channel
6.3. EUROPE
6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast
6.3.3.1. Germany market size and forecast
6.3.3.2. France market size and forecast
6.3.3.3. UK market size and forecast
6.3.3.4. Italy market size and forecast
6.3.3.5. Spain market size and forecast
6.3.3.6. Rest of Europe market size and forecast
6.3.4. Europe Naftifine Hydrochloride Ointment Market by Patient Group
6.3.5. Europe Naftifine Hydrochloride Ointment Market by Distribution Channel
6.4. ASIA-PACIFIC
6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast
6.4.3.1. Japan market size and forecast
6.4.3.2. China market size and forecast
6.4.3.3. Australia market size and forecast
6.4.3.4. India market size and forecast
6.4.3.5. South Korea market size and forecast
6.4.3.6. Taiwan market size and forecast
6.4.3.7. Rest of Asia-Pacific market size and forecast
6.4.4. Asia-Pacific Naftifine Hydrochloride Ointment Market by Patient Group
6.4.5. Asia-Pacific Naftifine Hydrochloride Ointment Market by Distribution Channel
6.5. LAMEA
6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast
6.5.3.1. Brazil market size and forecast
6.5.3.2. Turkey market size and forecast
6.5.3.3. Saudi Arabia market size and forecast
6.5.3.4. South Africa market size and forecast
6.5.3.5. Rest of LAMEA market size and forecast
6.5.4. LAMEA Naftifine Hydrochloride Ointment Market by Patient Group
6.5.5. LAMEA Naftifine Hydrochloride Ointment Market by Distribution Channel
CHAPTER 7 COMPANY PROFILES
7.1. MERZ DERMATOLOGY
7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments
7.2. PARCHEM FINE & SPECIALTY CHEMICALS
7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments
7.3. LGM PHARMA
7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments
7.4. SEBELA PHARMACEUTICALS, INC.
7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments
7.5. ERREGIERRE S.P.A
7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments
7.6. SIMAGCHEM CORPORATION
7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments
7.7. TARO PHARMACEUTICAL INDUSTRUES, LTD.
7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments
7.8. RENAISSANCE PHARMA, INC.,
7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments
7.9. SHANGHAI YISA BIOTECHNOLOGY CO., LTD.
7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments
7.10. SHAANXI TOP PHARM CHEMICAL CO., LTD.
7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments
Clients can easily download both quantitative as well as
qualitative reports in PDF and excel formats.
Start reading.
This Report and over 13,000+ thousand more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Buy Now *Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
